Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CareDxSTU:1K9 +9.20%68 EV-to-FCF is 22.95 as of Aug. 01, 2026. GuruFocus rates STU:1K9 with a GF Score™ of 68/100 and a GF Value™ of €20.12 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 100 Medical Diagnostics & Research companies, CareDx ranks worse than 54% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CareDx's Enterprise Value is €1,654.9 Mil.
CareDx's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €72.1 Mil. Therefore, CareDx's EV-to-FCF for today is 22.95.
The historical rank and industry rank for CareDx's EV-to-FCF or its related term are showing as below:
STU:1K9'
s EV-to-FCF Range Over the Past 10 Years
Min: -532.65 Med: -11.99 Max: 1165.58
Current: 22.67
During the past 13 years, the highest EV-to-FCF of CareDx was 1165.58. The lowest was -532.65. And the median was -11.99.
STU:1K9's EV-to-FCF is ranked worse than 54% of 100
companies
in the Medical Diagnostics & Research industry
Industry Median: 26.53
vs STU:1K9: 22.67
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-08-01), CareDx's stock price is €35.60.
CareDx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €1.798. Therefore, CareDx's PE Ratio (TTM) for today is 19.80.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CareDx's share price for today is €35.60.
CareDx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.798.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
CareDx EV-to-FCF Related Terms
CareDx EV-to-FCF Historical Data
* Premium members only.
The historical data trend for CareDx's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, CareDx's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CareDx EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, CareDx's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where CareDx's EV-to-FCF falls into.
CareDx's current Enterprise Value is €1,654.9 Mil.
CareDx's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €72.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CareDx (STU:1K9) has a EV-to-FCF of 22.95 as of Aug. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on CareDx and its competitors. According to the industry distribution chart, CareDx ranks #54 out of 100 companies in the Medical Diagnostics & Research industry, placing it in the top 54%.
Is CareDx's EV-to-FCF too high?
CareDx's current EV-to-FCF is 22.95. The Medical Diagnostics & Research industry median EV-to-FCF is 26.53. CareDx's value of 22.95 is 13.5% below this industry median. Based on the distribution chart, CareDx ranks #54 out of 100 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, CareDx has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CareDx's EV-to-FCF compare to NEO and WGS?
According to the Medical Diagnostics & Research industry distribution chart, CareDx ranks #54 out of 100 companies for EV-to-FCF. This places CareDx in the lower half of its industry. The industry median EV-to-FCF is 26.53. CareDx's value of 22.95 is 13.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 26.53, based on 100 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CareDx's current EV-to-FCF of 22.95 is 13.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on CareDx and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 26.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CareDx's current EV-to-FCF is 22.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CareDx stock overvalued right now?
Based on GuruFocus' analysis, CareDx (STU:1K9) is currently considered Significantly Overvalued. The stock's GF Value™ is €20.12, compared to a current price of €35.60 — trading 76.9% above its estimated fair value. The current EV-to-FCF is 22.95 and 13.5% below the Medical Diagnostics & Research industry median of 26.53. CareDx's overall GF Score™ is 68/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For CareDx (STU:1K9), the current EV-to-FCF is 22.95 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CareDx (STU:1K9) Overvalued in 2026?
Based on GuruFocus' analysis, CareDx stock appears to be overvalued.
The current stock price of €35.60 is trading 76.9% above its estimated GF Value™ of €20.12.
GuruFocus considers CareDx to be Significantly Overvalued.
Key valuation signals for STU:1K9:
EV-to-FCF: 22.95
GF Value™: €20.12 vs. price of €35.60 (76.9% above fair value)
Industry Position: 13.5% below the Medical Diagnostics & Research median (#54 of 100)
No single metric tells the full story. See the STU:1K9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
68GF Score
Get the complete analysis for STU:1K9
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1K9 has been successfully added to your 
